Delivers solid Q1 results, confirms core growth
and EPS for 2025 fiscal year
First-quarter fiscal year 2025
- Revenue of $1.68 billion for the first quarter ended Jan. 31,
2025, representing growth of 1.4% reported and up 1.2% on a core(1)
basis compared with the first quarter of 2024.
- GAAP net income of $318 million; earnings per share (EPS) of
$1.11, down 6% from the first quarter of 2024.
- Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2%
from the first quarter of 2024.
Outlook for full 2025 fiscal year and Q2
- Full-year revenue outlook is now in the range of $6.68 billion
to $6.76 billion, representing a range of up 2.6% to 3.8% reported
and 2.5% to 3.5% core(1). Non-GAAP EPS(3) is expected in the range
of $5.54 to $5.61 per share.
- Q2 revenue outlook is expected to be in the range of $1.61
billion to $1.65 billion, an increase of 2.4% to 4.9% reported and
up 2.5% to 5.0% core(1). Non-GAAP EPS(3) is expected in the range
of $1.25 to $1.28 per share.
Agilent Technologies Inc. (NYSE: A) today reported revenue of
$1.68 billion for the first quarter ended Jan. 31, 2025,
representing growth of 1.4% reported and up 1.2% core(1) compared
to the first quarter of 2024.
First-quarter GAAP net income was $318 million, or $1.11 per
share. This compares with $348 million, or $1.18 per share, in the
first quarter of fiscal year 2024. Non-GAAP(2) net income was $377
million, or $1.31 per share during the quarter, compared with $380
million or $1.29 per share during the year-ago quarter.
“The Agilent team delivered better than our expectations in Q1.
As a result of a solid start to the year, we’re maintaining our
core growth and EPS expectations for the year,” said Agilent
President and CEO Padraig McDonnell. “We have moved from planning
to execution on our market-first strategy we introduced at our
Analyst and Investor Day and are seeing the early benefits of our
Ignite Transformation to become nimbler and make decisions faster
in service to our customers.”
Financial Highlights
In the first quarter of 2025, Agilent implemented certain
changes to its segment reporting structure. Prior period segment
information has been recast to reflect these changes. These changes
have no impact on Agilent’s consolidated financial statements.
Life Sciences and Diagnostics Markets Group
Agilent’s Life Sciences and Diagnostics Markets Group (LDG)
reported first-quarter revenue of $647 million, an increase of 4%
reported and 1% core(1) year-over-year. LDG’s operating margin for
the quarter was 18.1%.
Agilent CrossLab Group
The Agilent CrossLab Group (ACG) reported first-quarter revenue
of $696 million, an increase of 1% reported and 3% core(1)
year-over-year. ACG’s operating margin for the quarter was
31.8%.
Applied Markets Group
The Applied Markets Group (AMG) reported first-quarter revenue
of $338 million, a decrease of 4% reported and 2% core(1)
year-over-year. AMG’s operating margin for the quarter was
25.0%.
Full Year 2025 and Second-Quarter Outlook
Full-year revenue outlook is now in the range of $6.68 billion
to $6.76 billion, representing growth of 2.6% to 3.8% reported,
while maintaining growth of 2.5% to 3.5% core(1). Non-GAAP EPS(3)
is still expected in the range of $5.54 to $5.61 per share.
The outlook for second-quarter revenue is expected to be in the
range of $1.61 billion to $1.65 billion, representing growth of
2.4% to 4.9% reported and up 2.5% to 5.0% core(1). Non-GAAP EPS(3)
is expected in the range of $1.25 to $1.28 per share.
The outlook is based on forecasted currency exchange rates.
Conference Call
Agilent’s management will present additional details regarding
the company’s first-quarter 2025 financial results on a conference
call with investors today at 1:30 p.m. PT. This event will be
broadcast live online in listen-only mode. To listen to the
webcast, select the “Q1 2025 Agilent Technologies Inc. Earnings
Conference Call” link on the Agilent Investor Relations website.
The replay of the call will remain on the company site for 90
days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers' most challenging questions. The company generated
revenue of $6.51 billion in fiscal year 2024 and employs
approximately 18,000 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and
Facebook.
Forward-Looking Statements
This news release contains forward-looking statements as defined
in the Securities Exchange Act of 1934 and is subject to the safe
harbors created therein. The forward-looking statements contained
herein include, but are not limited to, information regarding
Agilent’s growth prospects, business, financial results, revenue,
non-GAAP earnings guidance for Q2 and fiscal year 2025, and the
effects of its new organizational structure, operational
transformation and market-focused strategy. These forward-looking
statements involve risks and uncertainties that could cause
Agilent’s results to differ materially from management’s current
expectations. Such risks and uncertainties include, but are not
limited to, unforeseen changes in the strength of Agilent’s
customers’ businesses; unforeseen changes in the demand for current
and new products, technologies, and services; unforeseen changes in
the currency markets; customer purchasing decisions and timing; and
the risk that Agilent is not able to realize the savings expected
from integration and restructuring activities. In addition, other
risks that Agilent faces in running its operations include the
ability to execute successfully through business cycles; the
ability to meet and achieve the benefits of its operational
transformation, market-focused strategy and cost-reduction goals
and otherwise successfully adapt its cost structures to continuing
changes in business conditions; ongoing competitive, pricing and
gross-margin pressures; the risk that its cost-cutting initiatives
will impair its ability to develop products and remain competitive
and to operate effectively; the impact of geopolitical
uncertainties and global economic conditions on its operations, its
markets and its ability to conduct business; the ability to improve
asset performance to adapt to changes in demand; the ability of its
supply chain to adapt to changes in demand; the ability to
successfully introduce new products at the right time, price and
mix; the ability of Agilent to successfully integrate recent
acquisitions; the ability of Agilent to successfully comply with
certain complex regulations; and other risks detailed in Agilent’s
filings with the Securities and Exchange Commission, including its
annual report on Form 10-K for the fiscal year ended October 31,
2024. Forward-looking statements are based on the beliefs and
assumptions of Agilent’s management and on currently available
information. Agilent undertakes no responsibility to publicly
update or revise any forward-looking statement.
(1) Core revenue growth excludes the impact of currency and
acquisitions and divestitures within the past 12 months. Core
revenue is a non-GAAP measure. Reconciliations between GAAP revenue
and core revenue for Q1 fiscal year 2025 are set forth on page 6 of
the attached tables along with additional information regarding the
use of this non-GAAP measure. Core revenue growth rate as projected
for Q2 fiscal year 2025 and full fiscal year 2025 excludes the
impact of currency and acquisitions and divestitures within the
past 12 months. Most of the excluded amounts pertain to events that
have not yet occurred and are not currently possible to estimate
with a reasonable degree of accuracy and could differ materially.
Therefore, no reconciliation to GAAP amounts has been provided for
the projection.
(2) Non-GAAP net income and non-GAAP earnings per share
primarily exclude the impacts of restructuring and other related
costs, asset impairments, intangibles amortization,
transformational initiatives, acquisition and integration costs and
pension settlement loss. Agilent also excludes any tax benefits or
expenses that are not directly related to ongoing operations, and
which are either isolated or are not expected to occur again with
any regularity or predictability. A reconciliation between non-GAAP
net income and GAAP net income is set forth on page 4 of the
attached tables along with additional information regarding the use
of this non-GAAP measure.
(3) Non-GAAP earnings per share as projected for Q2 fiscal year
2025 and full fiscal year 2025 exclude primarily the estimated
impacts of non-cash intangibles amortization, transformational
initiatives, and acquisition and integration costs. Agilent also
excludes any tax benefits or expenses that are not directly related
to ongoing operations, and which are either isolated or are not
expected to occur again with any regularity or predictability. Most
of these excluded amounts pertain to events that have not yet
occurred and are not currently possible to estimate with a
reasonable degree of accuracy and could differ materially.
Therefore, no reconciliation to GAAP amounts has been provided.
Future amortization of intangibles is expected to be approximately
$27 million per quarter.
AGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED
STATEMENT OF OPERATIONS (In millions, except per share
data) (Unaudited) PRELIMINARY
Three Months Ended January 31,
2025
2024
Net revenue
$
1,681
$
1,658
Costs and expenses: Cost of products and services
782
750
Research and development
113
128
Selling, general and administrative
410
396
Total costs and expenses
1,305
1,274
Income from operations
376
384
Interest income
15
18
Interest expense
(28
)
(22
)
Other income (expense), net
4
23
Income before taxes
367
403
Provision for income taxes
49
55
Net income
$
318
$
348
Net income per share: Basic
$
1.12
$
1.19
Diluted
$
1.11
$
1.18
Weighted average shares used in computing net income per
share: Basic
285
293
Diluted
287
294
The preliminary income statement is estimated based
on our current information. Page 1
AGILENT
TECHNOLOGIES, INC. CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share data)
(Unaudited) PRELIMINARY January
31, October 31,
2025
2024
ASSETS Current assets: Cash and cash equivalents
$
1,467
$
1,329
Accounts receivable, net
1,328
1,324
Inventory
997
972
Other current assets
315
334
Total current assets
4,107
3,959
Property, plant and equipment, net
1,816
1,778
Goodwill
4,429
4,477
Other intangible assets, net
514
547
Long-term investments
173
175
Other assets
875
910
Total assets
$
11,914
$
11,846
LIABILITIES AND EQUITY Current liabilities: Accounts
payable
$
547
$
540
Employee compensation and benefits
258
368
Deferred revenue
612
544
Short-term debt
16
45
Other accrued liabilities
436
398
Total current liabilities
1,869
1,895
Long-term debt
3,347
3,345
Retirement and post-retirement benefits
120
130
Other long-term liabilities
551
578
Total liabilities
5,887
5,948
Total Equity: Stockholders' equity: Preferred stock; $0.01
par value; 125,000,000 shares authorized; none issued and
outstanding
—
—
Common stock; $0.01 par value, 2,000,000,000 shares authorized;
285,232,190 shares at January 31, 2025 and 285,193,011 shares at
October 31, 2024, issued and outstanding
3
3
Additional paid-in-capital
5,489
5,450
Retained earnings
916
750
Accumulated other comprehensive loss
(381
)
(305
)
Total stockholders' equity
6,027
5,898
Total liabilities and stockholders' equity
$
11,914
$
11,846
The preliminary balance sheet is estimated based on
our current information. Page 2
AGILENT
TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF CASH
FLOWS (In millions) (Unaudited)
PRELIMINARY Three Months Ended
January 31, January 31,
2025
2024
Cash flows from operating activities: Net income
$
318
$
348
Adjustments to reconcile net income to net cash provided by
operating activities: Depreciation and amortization
72
62
Share-based compensation
40
44
Deferred taxes expense (benefit)
(10
)
—
Excess and obsolete inventory related charges
10
11
Net (gain) loss on equity securities
(1
)
(3
)
Asset impairment charges
—
8
Other non-cash (income) expense, net
—
(6
)
Changes in assets and liabilities: Accounts receivable, net
(30
)
10
Inventory
(40
)
(9
)
Accounts payable
3
84
Employee compensation and benefits
(104
)
(104
)
Other assets and liabilities
173
40
Net cash provided by operating activities (a)
431
485
Cash flows from investing activities: Payments to acquire
property, plant and equipment
(97
)
(90
)
Payments in exchange for convertible note
(1
)
(5
)
Payments to acquire businesses and intangible assets, net of cash
acquired
4
—
Net cash used in investing activities
(94
)
(95
)
Cash flows from financing activities: Proceeds from issuance
of common stock under employee stock plans
30
34
Payment of taxes related to net share settlement of equity awards
(22
)
(25
)
Payments for repurchase of common stock
(90
)
—
Payments of dividends
(71
)
(69
)
Proceeds from issuance of long-term debt
4
—
Repayments of long-term debt
(1
)
(180
)
Net proceeds from (repayment of) short-term debt
(30
)
—
Net cash used in financing activities
(180
)
(240
)
Effect of exchange rate movements
(19
)
7
Net increase (decrease) in cash, cash equivalents and
restricted cash
138
157
Cash, cash equivalents and restricted cash at beginning of
period
1,332
1,593
Cash, cash equivalents and restricted cash at end of period
$
1,470
$
1,750
Reconciliation of cash, cash equivalents and
restricted cash to the condensed consolidated balance sheet:
Cash and cash equivalents
$
1,467
$
1,748
Restricted cash, included in other assets
3
2
Total cash, cash equivalents and restricted cash
$
1,470
$
1,750
(a) Cash payments included in operating activities:
Income tax payments, net of refunds received
$
19
$
24
Interest payments, net of capitalized interest
$
3
$
14
The preliminary cash flow is estimated based
on our current information. Page 3
AGILENT
TECHNOLOGIES, INC. NON-GAAP NET INCOME AND DILUTED EPS
RECONCILIATIONS (In millions, except per share data)
(Unaudited) PRELIMINARY Three Months
Ended January 31,
2025
2024
Net Income Diluted EPS Net Income Diluted
EPS GAAP net income
$
318
$
1.11
$
348
$
1.18
Non-GAAP adjustments: Restructuring and other related costs
1
—
3
0.01
Asset impairments
—
—
8
0.03
Intangible amortization
28
0.10
26
0.09
Transformational initiatives
6
0.02
3
0.01
Acquisition and integration costs
9
0.03
2
0.01
Pension settlement loss
14
0.05
—
—
Other
6
0.02
(6
)
(0.02
)
Adjustment for taxes (a)
(5
)
(0.02
)
(4
)
(0.02
)
Non-GAAP net income
$
377
$
1.31
$
380
$
1.29
(a) The adjustment for taxes excludes tax expense
(benefits) that management believes are not directly related to
on-going operations and which are either isolated, temporary or
cannot be expected to occur again with any regularity or
predictability such as the realized gain/loss due to sale of a
business, windfall benefits on stock compensation, and the impact
of R&D capitalization under section 174 of the Tax Cuts and
Jobs Act of 2017. For the three months ended January 31, 2025,
management used a non-GAAP effective tax rate of 12.50%. For the
three months ended January 31, 2024, management used a non-GAAP
effective tax rate of 13.50%. We provide non-GAAP net income and
non-GAAP net income per share amounts in order to provide
meaningful supplemental information regarding our operational
performance and our prospects for the future. These supplemental
measures exclude, among other things, charges related to
restructuring and other related costs, asset impairments,
amortization of intangibles, transformational initiatives,
acquisition and integration costs and pension settlement loss.
Restructuring and other related costs include incremental
expenses incurred in the period associated with restructuring
programs, usually aimed at changes in business and/or cost
structure. Such costs may include one-time termination benefits,
facility-related costs and contract termination fees.
Asset impairments include assets that have been written down
to their fair value.
Transformational initiatives
include expenses associated with targeted cost reduction activities
such as manufacturing transfers including costs to move
manufacturing, site consolidations, legal entity and other business
reorganizations, insourcing or outsourcing of activities. Such
costs may include move and relocation costs, one-time termination
benefits and other one-time reorganization costs. Included in this
category are also expenses associated with company programs to
transform our product lifecycle management (PLM) system and human
resources and financial systems.
Acquisition and
integration costs include all incremental expenses incurred to
effect a business combination. Such acquisition costs may include
advisory, legal, tax, accounting, valuation, and other professional
or consulting fees. Such integration costs may include expenses
directly related to integration of business and facility
operations, the transfer of assets and intellectual property,
information technology systems and infrastructure and other
employee-related costs.
Pension settlement loss
resulted from the transfer of the Netherlands defined benefit plan
to an unaffiliated insurance company.
Other includes
certain legal costs and settlements, special compliance costs,
acceleration of stock-based compensation expense and other
miscellaneous adjustments. Our management uses non-GAAP
measures to evaluate the performance of our core businesses, to
estimate future core performance and to compensate employees. Since
management finds this measure to be useful, we believe that our
investors benefit from seeing our results “through the eyes” of
management in addition to seeing our GAAP results. This information
facilitates our management’s internal comparisons to our historical
operating results as well as to the operating results of our
competitors. Our management recognizes that items such as
amortization of intangibles can have a material impact on our cash
flows and/or our net income. Our GAAP financial statements
including our statement of cash flows portray those effects.
Although we believe it is useful for investors to see core
performance free of special items, investors should understand that
the excluded items are actual expenses that may impact the cash
available to us for other uses. To gain a complete picture of all
effects on the company’s profit and loss from any and all events,
management does (and investors should) rely upon the GAAP income
statement. The non-GAAP numbers focus instead upon the core
business of the company, which is only a subset, albeit a critical
one, of the company’s performance. Readers are reminded that
non-GAAP numbers are merely a supplement to, and not a replacement
for, GAAP financial measures. They should be read in conjunction
with the GAAP financial measures. It should be noted as well that
our non-GAAP information may be different from the non-GAAP
information provided by other companies. The preliminary
non-GAAP net income and diluted EPS reconciliation is estimated
based on our current information. Page 4
AGILENT
TECHNOLOGIES, INC. SEGMENT INFORMATION (In millions,
except where noted) (Unaudited) PRELIMINARY
Quarter-over-Quarter Life Sciences
and Diagnostics Markets Segment Q1'25 Q1'24
Revenue
$
647
$
620
Gross Margin, %
52.8
%
54.9
%
Income from Operations
$
117
$
114
Operating margin, %
18.1
%
18.4
%
Agilent CrossLab Segment Q1'25
Q1'24 Revenue
$
696
$
686
Gross Margin, %
56.1
%
56.9
%
Income from Operations
$
221
$
222
Operating margin, %
31.8
%
32.4
%
Applied Markets Segment Q1'25
Q1'24 Revenue
$
338
$
352
Gross Margin, %
55.8
%
56.4
%
Income from Operations
$
84
$
92
Operating margin, %
25.0
%
26.1
%
Income from operations reflect the results of our
reportable segments under Agilent's management reporting system
which are not necessarily in conformity with GAAP financial
measures. Income from operations of our reporting segments exclude,
among other things, charges related to restructuring and other
related costs, asset impairments, amortization of intangibles,
transformational initiatives and acquisition and integration costs.
Readers are reminded that non-GAAP numbers are merely a
supplement to, and not a replacement for, GAAP financial measures.
They should be read in conjunction with the GAAP financial
measures. It should be noted as well that our non-GAAP information
may be different from the non-GAAP information provided by other
companies. The preliminary segment information is estimated
based on our current information. Page 5
AGILENT
TECHNOLOGIES, INC. RECONCILIATIONS OF REVENUE BY SEGMENT
EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY
ADJUSTMENTS (CORE) (In millions) (Unaudited)
PRELIMINARY Year-over-Year GAAP
Year-over-Year GAAP Revenue by
Segment Q1'25 Q1'24 % Change
Life Sciences and Diagnostics Markets Segment
$
647
$
620
4
%
Agilent CrossLab Segment
696
686
1
%
Applied Markets Segment
338
352
(4
%)
Agilent
$
1,681
$
1,658
1
%
Non-GAAP(excluding Acquisitions
& Divestitures) Year-over-Yearat Constant Currency
(a) Year-over-Year Year-over-Year Percentage
Point Impact from Currency Current Quarter Currency Impact
(b) Non GAAP Revenue by
Segment Q1'25 Q1'24 % Change %
Change Life Sciences and Diagnostics Markets Segment
$
621
$
620
—
1
%
-1 ppt
$
(6
)
Agilent CrossLab Segment
696
686
1
%
3
%
-2 ppts
(11
)
Applied Markets Segment
338
352
(4
%)
(2
%)
-2 ppts
(5
)
Agilent (Core)
$
1,655
$
1,658
—
1
%
-1 ppt
$
(22
)
We compare the year-over-year change in
revenue excluding the effect of recent acquisitions and
divestitures and foreign currency rate fluctuations to assess the
performance of our underlying business. (a) The constant
currency year-over-year growth percentage is calculated by
recalculating all periods in the comparison period at the foreign
currency exchange rates used for accounting during the last month
of the current quarter and then using those revised values to
calculate the year-over-year percentage change. (b) The
dollar impact from the current quarter currency impact is equal to
the total year-over-year dollar change less the constant currency
year-over-year change. The preliminary reconciliation of
GAAP revenue adjusted for recent acquisitions and divestitures and
impact of currency is estimated based on our current information.
Page 6
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250226303369/en/
Investor Contact: Parmeet Ahuja +1 408-345-8948
parmeet_ahuja@agilent.com
Media Contact: Andréa Topper +1 408-709-0060
andrea.topper@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2025 to Mar 2025
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Mar 2025